表紙
市場調査レポート

Toleranzia ABの製品パイプライン分析

Toleranzia AB - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 285614
出版日 ページ情報 英文 21 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
Toleranzia ABの製品パイプライン分析 Toleranzia AB - Product Pipeline Review - 2015
出版日: 2015年12月23日 ページ情報: 英文 21 Pages
概要

Toleranzia ABはスウェーデンに本社をもつバイオテクノロジー企業で、自己免疫疾患治療薬の開発、技術提供を行っています。融合タンパク質を利用し免疫機能不全を治療する技術プラットフォームをベースに、希少疾患、?型糖尿病、リウマチ性関節炎、多発性硬化症などの治療薬を提供しています。

当レポートでは、Toleranzia ABにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Toleranzia ABの基本情報

  • Toleranzia ABの概要
  • 主要情報
  • 企業情報

Toleranzia AB:R&Dの概要

  • 主な治療範囲

Toleranzia AB:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Toleranzia AB:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

Toleranzia AB:薬剤プロファイル

  • Recombinant Protein for Allergy
  • Recombinant Protein for Autoimmune Orphan Indications
  • Recombinant Protein for Multiple Sclerosis
  • Recombinant Protein for Myasthenia Gravis
  • Recombinant Protein for Rheumatoid Arthritis
  • Recombinant Protein for Sjogren's syndrome
  • Recombinant Protein for Type 1 Diabetes

Toleranzia AB:パイプライン分析

  • 投与経路別
  • 分子タイプ別

Toleranzia AB:本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07898CDB

Summary

Global Markets Direct's, 'Toleranzia AB - Product Pipeline Review - 2015', provides an overview of the Toleranzia AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Toleranzia AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Toleranzia AB including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Toleranzia AB's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Toleranzia AB's pipeline products

Reasons to buy

  • Evaluate Toleranzia AB's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Toleranzia AB in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Toleranzia AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Toleranzia AB and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Toleranzia AB
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Toleranzia AB and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Toleranzia AB Snapshot
    • Toleranzia AB Overview
    • Key Information
    • Key Facts
  • Toleranzia AB - Research and Development Overview
    • Key Therapeutic Areas
  • Toleranzia AB - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Toleranzia AB - Pipeline Products Glance
    • Toleranzia AB - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Toleranzia AB - Drug Profiles
    • Recombinant Protein for Allergy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Autoimmune Orphan Indications
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Multiple Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Myasthenia Gravis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Rheumatoid Arthritis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Sjogren's Syndrome
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Type 1 Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Toleranzia AB - Pipeline Analysis
  • Toleranzia AB - Pipeline Products by Route of Administration
  • Toleranzia AB - Pipeline Products by Molecule Type
  • Toleranzia AB - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Toleranzia AB, Key Information
  • Toleranzia AB, Key Facts
  • Toleranzia AB - Pipeline by Indication, 2015
  • Toleranzia AB - Pipeline by Stage of Development, 2015
  • Toleranzia AB - Monotherapy Products in Pipeline, 2015
  • Toleranzia AB - Preclinical, 2015
  • Toleranzia AB - Pipeline by Route of Administration, 2015
  • Toleranzia AB - Pipeline by Molecule Type, 2015

List of Figures

  • Toleranzia AB - Pipeline by Top 10 Indication, 2015
Back to Top